A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis (NCT07588568) | Clinical Trial Compass
Not Yet RecruitingPhase 2
A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis
United States52 participantsStarted 2026-07
Plain-language summary
The goal of this study is to find out if a medication called upadacitinib can help treat a condition called Eosinophilic Esophagitis (EoE).
The main question it aims to answer are:
\- Does upadacitinib in addition to topical corticosteroids help reduce EoE disease activity?
Participants will:
* Take upadacitinib or placebo every day for 12 weeks, followed by 12 weeks of upadacitinib
* Fill out surveys and answer health questions
* Visit the clinic every 4 weeks for checkups and tests
Who can participate
Age range
18 Years – 65 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age 18-65 years.
. Diagnosis of EoE per 2018 AGREE consensus guidelines.
. Currently using topical corticosteroids (TCS) for EoE treatment (either swallowed budesonide, ≥2mg total daily dose or swallowed fluticasone, ≥1760 mcg total daily dose) for at least 8 weeks (prior to the screening endoscopy) and willing to remain on the same TCS treatment with no changes to regimen throughout the study.
. Have active esophageal eosinophilia (peak eosinophil count ≥15 eos/hpf \[eosinophils per high power field\]) as measured during the screening endoscopy despite ongoing therapy with TCS.
. Have active symptoms of esophageal dysfunction attributed to EoE (such as trouble swallowing, heartburn, reflux, vomiting, chest pain, painful swallowing, abdominal pain, malnutrition, etc.) in the 4 weeks prior to the screening endoscopy.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Peak eosinophil count (measured in eos/hpf) after 12-weeks of treatment
. Willing to continue all current EoE treatments (including medications such as proton pump inhibitors (PPIs), diet elimination, etc.) throughout participation in the study.
. Able to read, comprehend, and sign consent form.
. Ability to take oral medication (swallow a pill) and be willing to adhere to the study regimen (follow dosing instructions and complete study procedures).
Exclusion criteria
. Use of systemic corticosteroids (such as prednisone or methylprednisolone) within 4 weeks of the screening endoscopy.
. Use of dupilumab (dupixent) within 3 months of the screening endoscopy.
. Use of estrogen (including estrogen-containing contraceptives and other hormonal treatments) within 30 days of screening.
. Previous esophageal resection.
. Medical instability making it unsafe to perform an upper endoscopy.
. At the Screening / Baseline or Enrollment Visit, meeting any of the following conditions:
.1. Two or more prior episodes of herpes zoster (shingles), or one or more episodes of disseminated herpes zoster;
.2. One or more prior episodes of disseminated herpes simplex (including eczema herpeticum);